Developed by Danish drugmaker Novo Nordisk, and FDA-approved in 2017, Ozempic lowers blood sugar by helping the body make more insulin through weekly injections.
Its main aim is to help adults who suffer from type 2 diabetes to manage their blood sugar. They use semaglutide to mimic a naturally occurring hormone, which communicates to the brain that you are full. The chemical also slows digestion, increasing how long food should process and leave the body.